Powerpoint presentation by dr sathiha

23
Standard BEACOPP Standard BEACOPP Chemotherapy Compared with Chemotherapy Compared with COPP-ABVD for COPP-ABVD for Advanced Advanced Hodgkin's Disease Hodgkin's Disease Moscow State University Moscow State University Faculty of Fundamental Medicine Faculty of Fundamental Medicine N.N.Blokhin Cancer Research Center Presented By : Dr .Sa Thi Ha (M.B;B.S) Supervisor : Prof Dr.B.I.Polyakov Dr.D.A.Bykov 17 th may 2010

description

 

Transcript of Powerpoint presentation by dr sathiha

Page 1: Powerpoint presentation by dr sathiha

Standard BEACOPP Chemotherapy Standard BEACOPP Chemotherapy Compared with COPP-ABVD for Compared with COPP-ABVD for Advanced Hodgkin's DiseaseAdvanced Hodgkin's Disease

Moscow State UniversityMoscow State UniversityFaculty of Fundamental MedicineFaculty of Fundamental MedicineN.N.Blokhin Cancer Research Center

Presented By : Dr .Sa Thi Ha (M.B;B.S)Supervisor : Prof Dr.B.I.Polyakov Dr.D.A.Bykov17th may 2010

Page 2: Powerpoint presentation by dr sathiha

Introduction Hodgkin lymphoma is characterized by the

presence of a special type of lymphatic cell called a Reed-Sternberg (RS) cell.

look like "owl's eyes.

more common in young adults and elderly patients.

Page 3: Powerpoint presentation by dr sathiha

Reed-Sternberg cell

Page 4: Powerpoint presentation by dr sathiha

population8510 new cases (2009)

4640males and 3870 females

1290 died (800 males and 490 females in 2009)

Page 5: Powerpoint presentation by dr sathiha

Risk factors Age Family history SexPast Epstein-Barr infectionCompromised immune systemGeography Socioeconomic status

Page 6: Powerpoint presentation by dr sathiha

Signs and symptom (+) of B symptomsAlcohol-induced pain in the enlarged nodes Enlarged lymph nodes (firm and rubbery)Hepatosplenomegaly Back pain Petechiae

Page 7: Powerpoint presentation by dr sathiha

Diagnosis History taking and physical examination Investigation Blood cell count (ESR) MRI PET scan Biopsy BM examination

Page 8: Powerpoint presentation by dr sathiha

Treatment Chemotherapy RadiotherapyStem cell transplantSurgery Target therapy Immunotherapy

Page 9: Powerpoint presentation by dr sathiha

Chemotherapy ABVD(Adriamycin, bleomycin, vinblastine

and dacarbazine).BEACOPP(bleomycin, etoposide,

doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).

Stanford V( doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin and prednisone).

COPP/ABVD(cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine and dacarbazine)

MOPP( mechlorethamine, vincristine, procarbazine and prednisone)

Page 10: Powerpoint presentation by dr sathiha

The studied prognostic factors Age >45 year versus <45 Gender Type of disease: early disease versus advanced

disease Presence of B symptoms ESR > 50 or > 30 plus B symptoms versus neither LDH > 500 IU/L versus < 500 IU /L Extranodal involvement Mediastinal involvement Pathological subtypes Type of chemotherapy

Page 11: Powerpoint presentation by dr sathiha

Aim of study

To identify various methods of combination therapy in advanced Hodgkin’s lymphoma and which is best and less toxicity.

Page 12: Powerpoint presentation by dr sathiha

Research objective To evaluate rate of freedom from treatment failure

at 5 years in treatment of standard BEACOPP and ABVD-COPP

To identify outcome and 5 years survival rates in standard BEACOPP and ABVD-COPP

To determine the toxicity of long term chemotherapy

Page 13: Powerpoint presentation by dr sathiha

Methods and materials Study method … retrospective method No of patients …49 patients(25-BEACOPP

and 24-COPP-ABVD)Duration of study …January 2005 to

December 2009.Staging …Ann Arbor clinical stage IIB or IIIA

and above stage with a large mediastinal mass Work-up - chest x-ray, CT of the abdomen and

pelvis, and complete blood count and ESR with metabolic profile

Page 14: Powerpoint presentation by dr sathiha

55 patients recruited

28 Assigned to BEACOPP27 Assigned to COPP-ABVD

2 Excluded 2 did not have Hodgkin’s disease

2 Excluded 2 did not have Hodgkin’s disease

26 Eligible 1 lost to follow up 25 Elgible 1 lost to follow up

25 Included in the analysis 23 received full course 2 received partial course

24 Included in the analysis 20 received full course 4 received partial course

Numbers of patients included in this analysis

Page 15: Powerpoint presentation by dr sathiha

Characteristics of patients

Page 16: Powerpoint presentation by dr sathiha

Chacteristics of patients by stage

Page 17: Powerpoint presentation by dr sathiha

Acute Adverse Effects of Chemotherapy

Page 18: Powerpoint presentation by dr sathiha

Kaplan–Meier Analysis of the Probability of Freedom from Treatment Failure (Panel A) and Overall Survival (Panel B)

Page 19: Powerpoint presentation by dr sathiha

Rate of the early progression and Five year Kaplain-Meier estimates of

the rate of free from treatment failure according to the International

Prognostic Index.

International Prognostic IndexCOPP-ABVD

(%)

Standard

BEACOPP(%)Early progression Good (0-1)Fair (2-3)Poor (4-7)Freedom from treatment failure at 5 yearsGood (0-1)Fair (2-3)Poor (4-7)Overall survival at 5 years Good (0-1)Fair (2-3)Poor (4-7)

101118

796759

928467

699

817274

938681

Page 20: Powerpoint presentation by dr sathiha

Outcome of Treatment and Five-Year Survival Rates.

Variable

COPP-ABVD(N=24)

Standard BEACOPP(N=25) percent

Complete remission 85(80-89) 88(85-91)

Early progression 10(7-15) 8(5-10)

Freedom from treatment failure at 5 yr

69(63-75) 76(72-80)

Overall survival at 5 yr 83(78-87) 88(85-91)

Page 21: Powerpoint presentation by dr sathiha

Conclusion The rate of freedom from treatment failure at five years

was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group.

The five-year rates of overall survival were 83percent COPP-ABVD, the comparison with 88 percent of BEACOPP group. Standard BEACOPP results in better tumor control and overall survival than did COPP-ABVD.

The incidence of acute toxicity increases with BEACOPP; grade 4 leukopenia occurred in one or more cycles.

Page 22: Powerpoint presentation by dr sathiha
Page 23: Powerpoint presentation by dr sathiha

Thank you for attention